Annie Blobaum

VP, Nonclinical Development at Appello Pharmaceuticals

Dr. Blobaum holds a doctorate degree in Pharmacology from the University of Michigan and undergraduate degrees in Chemistry and Biology from West Virginia University. Prior to moving into the drug discovery and development arena, Dr. Blobaum pursued post-doctoral studies and a research faculty position in the Department of Biochemistry at Vanderbilt University. In 2010, Dr. Blobaum joined the Vanderbilt (now Warren) Center for Neuroscience Drug Discovery (WCNDD) as a project leader in drug metabolism and pharmacokinetics (DMPK). For more than 10 years, Dr. Blobaum served as a team lead in the WCNDD, co-director of DMPK, and as research faculty in the Department of Pharmacology at Vanderbilt University.

During her tenure at the WCNDD, Dr. Blobaum’s focus was on the discovery and development of novel therapeutics for the treatment of Parkinson’s disease, schizophrenia, Alzheimer’s disease, and other neurological disorders. Her group was integrally involved in supporting chemistry and pharmacology team efforts in the hit-to-lead and lead optimization processes to identify potential drug candidates. Dr. Blobaum’s areas of expertise include: defining mechanisms of clearance, P450 metabolism/inhibition/induction, non-P450 contributions to metabolism, metabolite identification/biotransformation, drug efflux, IVIVC, human PK predictions, and PK-PD relationships.

Timeline

  • VP, Nonclinical Development

    Current role